Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 58 Breast Neoplasms 43 Prostatic Neoplasms 32 Lung Neoplasms 29 Multiple Myeloma 23 Neoplasms 22 Parkinson Disease 4, Autosomal Dominant Lewy Body 17 Ovarian Neoplasms 17 Colorectal Neoplasms 17 Neoplasm Metastasis 16 Leukemia, Lymphocytic, Chronic, B-Cell 16 Carcinoma, Renal Cell 14 Pancreatic Neoplasms 13 Endometrial Neoplasms 12 Small Cell Lung Carcinoma 11 Urinary Bladder Neoplasms 10 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 10 Myasthenia Gravis 9 Lymphoma, Follicular 9 Leukemia, Myeloid, Acute 9 Fallopian Tube Neoplasms 9 Non-Muscle Invasive Bladder Neoplasms 8 Colonic Neoplasms 8 Burkitt Lymphoma 7 Recurrence 6 Lymphoma, Mantle-Cell 6 Esophageal Neoplasms 6 Adenocarcinoma 6 Triple Negative Breast Neoplasms 5

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma, Cutaneous Malignant × 30 days × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡